Allergan Announces Ratio for Distribution of Common Stock of Advanced Medical Optics.Business Editors IRVINE, Calif.--(BUSINESS WIRE)--June 4, 2002 Allergan, Inc. (NYSE NYSE See: New York Stock Exchange :AGN AGN Again (Amateur Radio) AGN Active Galactic Nucleus AGN Acute Glomerulonephritis AGN Accountants Global Network AGN Air Gabon (ICAO code) ) today announced the share ratio for the special tax-free dividend of Advanced Medical Optics Advanced Medical Optics, Inc., (NYSE: EYE) (known as AMO) is a global medical device leader focused on the discovery and delivery of innovative vision technologies that optimize the quality of life for people of all ages. (AMO AMO - America's Multimedia Online ) shares to effect the previously announced spin-off of Allergan's subsidiary, AMO. On the date of the spin-off, currently anticipated to occur on or about June 29, 2002, each holder of Allergan common stock as of June 14, 2002 (the record date) will be entitled to one (1) share of AMO common stock for every four and one half (4.5) shares of Allergan common stock held as of the record date. Any fractional shares will be paid in cash. As of the spin-off, AMO will be established as a separate, publicly traded company publicly traded company A company whose shares of common stock are held by the public and are available for purchase by investors. The shares of publicly traded firms are bought and sold on the organized exchanges or in the over-the-counter market. . The completion of the spin-off and the issuance of the special tax-free dividend are subject to the satisfaction of certain conditions previously imposed by Allergan's Board of Directors including, but not limited to, the corporate restructuring associated with the spin-off, the completion of a debt financing Debt Financing When a firm raises money for working capital or capital expenditures by selling bonds, bills, or notes to individual and/or institutional investors. In return for lending the money, the individuals or institutions become creditors and receive a promise to repay by AMO, and compliance with federal and state securities laws. Forward-Looking Statements In this press release, forward-looking statements such as the timing of the spin-off of AMO, are forward-looking. All forward-looking statements in this press release reflect Allergan's analysis and intentions only as of the date of this press release. Actual events may differ from current expectations based on a number of factors, including the uncertainties associated with effecting a spin-off of a separate public company and the discretion of Allergan's Board of Directors to delay or cancel the spin-off of AMO prior to its consummation. Therefore, the reader is cautioned not to rely on these forward-looking statements. Allergan disclaims any intent or obligation to update these forward-looking statements. Allergan, Inc. Allergan, Inc., headquartered in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens contact lens, thin plastic lens worn between the eye and eyelid that may be used instead of eyeglasses. Actors, models, and others wear them for appearance, and athletes use them for safety and convenience. care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs and improve patients' lives. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion